Cargando…

Suicidality and Cannabidiol: Opportunities and Challenges

Cannabidiol (CBD) is gaining considerable attention in the research community with promising results in a variety of neuropsychiatric conditions. In particular, there are replicated findings for the therapeutic effects of CBD on psychotic and anxiety symptoms as well as substance use disorders, all...

Descripción completa

Detalles Bibliográficos
Autores principales: Moazen-Zadeh, Ehsan, Galynker, Igor I.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Bentham Science Publishers 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8686298/
https://www.ncbi.nlm.nih.gov/pubmed/33059579
http://dx.doi.org/10.2174/1570159X18666201015160417
_version_ 1784617988389863424
author Moazen-Zadeh, Ehsan
Galynker, Igor I.
author_facet Moazen-Zadeh, Ehsan
Galynker, Igor I.
author_sort Moazen-Zadeh, Ehsan
collection PubMed
description Cannabidiol (CBD) is gaining considerable attention in the research community with promising results in a variety of neuropsychiatric conditions. In particular, there are replicated findings for the therapeutic effects of CBD on psychotic and anxiety symptoms as well as substance use disorders, all of which are highly prevalent in patients who present with suicidality. Meanwhile, there has been a lack of suicide research on cannabidiol. This perspective provides an overview of the available evidence, potential reasons behind the halt in suicide research on cannabidiol, and recommendations for future investigations.
format Online
Article
Text
id pubmed-8686298
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Bentham Science Publishers
record_format MEDLINE/PubMed
spelling pubmed-86862982022-01-13 Suicidality and Cannabidiol: Opportunities and Challenges Moazen-Zadeh, Ehsan Galynker, Igor I. Curr Neuropharmacol Article Cannabidiol (CBD) is gaining considerable attention in the research community with promising results in a variety of neuropsychiatric conditions. In particular, there are replicated findings for the therapeutic effects of CBD on psychotic and anxiety symptoms as well as substance use disorders, all of which are highly prevalent in patients who present with suicidality. Meanwhile, there has been a lack of suicide research on cannabidiol. This perspective provides an overview of the available evidence, potential reasons behind the halt in suicide research on cannabidiol, and recommendations for future investigations. Bentham Science Publishers 2021-05-27 2021-05-27 /pmc/articles/PMC8686298/ /pubmed/33059579 http://dx.doi.org/10.2174/1570159X18666201015160417 Text en © 2021 Bentham Science Publishers https://creativecommons.org/licenses/by-nc/4.0/ This is an open access article licensed under the terms of the Creative Commons Attribution-Non-Commercial 4.0 International Public License (CC BY-NC 4.0) (https://creativecommons.org/licenses/by-nc/4.0/legalcode), which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.
spellingShingle Article
Moazen-Zadeh, Ehsan
Galynker, Igor I.
Suicidality and Cannabidiol: Opportunities and Challenges
title Suicidality and Cannabidiol: Opportunities and Challenges
title_full Suicidality and Cannabidiol: Opportunities and Challenges
title_fullStr Suicidality and Cannabidiol: Opportunities and Challenges
title_full_unstemmed Suicidality and Cannabidiol: Opportunities and Challenges
title_short Suicidality and Cannabidiol: Opportunities and Challenges
title_sort suicidality and cannabidiol: opportunities and challenges
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8686298/
https://www.ncbi.nlm.nih.gov/pubmed/33059579
http://dx.doi.org/10.2174/1570159X18666201015160417
work_keys_str_mv AT moazenzadehehsan suicidalityandcannabidiolopportunitiesandchallenges
AT galynkerigori suicidalityandcannabidiolopportunitiesandchallenges